Collaborations

Alliance to develop, commercialize influenza vaccines

Published in TB and Outbreaks Week, February 3rd, 2004

Aventis (AVE) and Crucell N.V. (CRXL) announced that they have entered into a strategic agreement to further develop and commercialize novel influenza vaccine products based on Crucell's proprietary PER.C6 cell line technology.

The agreement covers both pandemic and epidemic influenza vaccines, which up to now have been part of Crucell's in-house product development program.

Under the terms of the agreement, Aventis Pasteur, the vaccines business of Aventis, receives an exclusive license to research, develop, manufacture, and market cell-based influenza vaccines using Crucell's unique PER.C6 cell line technology. Crucell will receive milestone...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry